Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 38 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 5/23/2007


1.		Phase II/III Chemotherapy with MVP (MITO/VBL/CACP) vs CHIP vs CBDCA vs VBL/CACP vs MVP-CAMP (MITO/VBL/CACP/CTX/ADR/MTX/PCB) in Patients with Metastatic (Stage III) non-Small Cell Bronchogenic Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-1583


2.		Phase II/III Comparison of the Platinum Compounds CBDCA vs CHIP vs CACP for Recurrent or Metastatic Epidermoid Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								UMCC-8223

Last Modified: 4/12/2007


3.		Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				1 to 21				NCI				POG-8741/42 POG-8741, POG-8742

Last Modified: 7/5/2007


4.		Phase III Randomized Comparison of Combination Chemotherapy with CBDCA/CTX vs CACP/CTX in Patients with Stage III/IV Ovarian Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase I				Treatment				Completed				18 and over				NCI				SWOG-8412


5.		Phase I/II Intraperitoneal Chemotherapy with CHIP in Patients with Intra-Abdominal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				under 80				NCI				CHNMC-IRB-5141 NCI-T85-0105D, T85-0105


6.		Phase I/II Intraperitoneal Chemotherapy with CHIP in Patients with Intra-Abdominal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to physiologic 80								NCOG-P-5O851 NCOG-P-5O-85-1


7.		Phase II Master Protocol for Single-Agent and Combination Chemotherapy for Locally Advanced or Metastatic non-Small Cell Lung Cancer --- CBDCA vs CHIP (Summary Last Mofified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				CLB-8431 CALGB-8431


8.		Phase II Randomized Chemotherapy with CBDCA vs CHIP for Locally Advanced, Recurrent, or Metastatic Squamous Cell Carcinoma of the Cervix

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				no age specified				NCI				GOG-77


9.		Phase II Chemotherapy with Platinum IV vs Carboplatin for Advanced Transitional Cell Carcinoma of the Urothelium

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				EST-4883 SEG-INT-GU-202

Last Modified: 10/15/2007


10.		Phase II CBDCA vs CHIP for Advanced or Recurrent Squamous Cell Cancer of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				SWOG-8371

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute